Mark S. Morginstin
Expertise in
24
conditions

Dr. Mark S. Morginstin

Hematology | Cardiology | Oncology
Einstein Healthcare Network Hematology Oncology
609 W Germantown Pike, Ste 280, 
East Norriton, PA 
Offers Telehealth
Expertise in
24
conditions
Einstein Healthcare Network Hematology Oncology
609 W Germantown Pike, Ste 280, 
East Norriton, PA 

Overview

Mark Morginstin is a Hematologist and a Cardiologist practicing medicine in East Norriton, Pennsylvania.

Dr. Morginstin is highly rated in 24 conditions, according to our data. His clinical expertise encompasses Paget Disease of the Breast, Inflammatory Breast Cancer, Thrombocytopenia, Breast Cancer, and Liver Embolization.

Dr. Morginstin is board certified in Hematology, Internal Medicine, and Medical Oncology. He is actively involved in clinical research, co-authoring 6 peer reviewed articles and participating in 6 clinical trials.

Graduate Institution

University Of Medicine And Dentistry Of NJ

Specialties

Hematology
Cardiology
Oncology

Licenses

Internal Medicine in CT

Board Certifications

Hematology
Internal Medicine
Medical Oncology

Hospital Affiliations

Jefferson Einstein Montgomery Hospital
Jefferson Einstein Philadelphia Hospital
Jefferson Einstein Philadelphia Hospital
Jefferson Lansdale Hospital
Jefferson Einstein Montgomery Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Community Health Choice
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
First Health
  • INSURANCE PLAN
  • MEDICARE PDP
  • PPO
Gateway Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • OTHER MEDICARE PART D
Geisinger
  • HMO
  • POS
  • PPO
Health Partners Plans
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
PA Health and Wellness
  • HMO
  • MANAGED MEDICAID PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 15 Less Insurance Carriers -

Locations

Einstein Healthcare Network Hematology Oncology
609 W Germantown Pike, Ste 280, East Norriton, PA 19403
Other Locations
Minerva D. Braemer Medical Arts Building
609 West Germantown Pike, East Norriton, PA 19403
Minerva and Fred Braemer Heart Center
5501 Old York Road, Floor 1, Philadelphia, PA 19141

Additional Areas of Focus

Dr. Morginstin has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Anemia
Adrenal Cancer
Metastatic Uveal Melanoma
Anal Cancer
Aplastic Anemia

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 02, 2026
Intervention Type: Other
Study Phase: Phase 3
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Exemestane, Letrozole, Systemic Chemotherapy
Study Phase: Phase 3
A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor-Positive Advanced Breast Cancer
A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor-Positive Advanced Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Other, Procedure, Drug
Study Drugs: Entinostat, Exemestane, Goserelin, Goserelin Acetate
Study Phase: Phase 3
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: May 06, 2026
Intervention Type: Drug, Other
Study Drugs: Carboplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Paclitaxel
Study Phase: Phase 3
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 24, 2026
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
View 4 Less Clinical Trials

6 Total Publications

Bleeding through the strains: an elderly woman's battle with post-transfusion purpura and acute alveolar haemorrhage.
Bleeding through the strains: an elderly woman's battle with post-transfusion purpura and acute alveolar haemorrhage.
Journal: BMJ case reports
Published: June 22, 2025
Similar Doctors
Expertise in
12
conditions
Dr. Janet L. Kwiatkowski
Hematology | Oncology
Expertise in
12
conditions
Dr. Janet L. Kwiatkowski
Hematology | Oncology
Referral may be required

Office

3401 Civic Center Blvd, 
Philadelphia, PA 
 (16.2 miles away)
215-590-1000
Languages Spoken:
English
See accepted insurances

Janet Kwiatkowski is a Hematologist and an Oncologist practicing medicine in Philadelphia, Pennsylvania. Dr. Kwiatkowski is highly rated in 12 conditions, according to our data. Her clinical expertise encompasses Hemolytic Anemia, Congenital Hemolytic Anemia, Anemia, Bone Marrow Transplant, and Splenectomy.

Expertise in
13
conditions
Dr. John M. Maris
Hematology | Oncology
Expertise in
13
conditions
Dr. John M. Maris
Hematology | Oncology
Referral may be required

Office

3500 Civic Center Blvd, 
Philadelphia, PA 
 (16.3 miles away)
215-590-3025
Languages Spoken:
English

John Maris is a Hematologist and an Oncologist practicing medicine in Philadelphia, Pennsylvania. Dr. Maris is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Neuroblastoma, Embryonal Tumor with Multilayered Rosettes, Gliomatosis Cerebri, and Rhabdomyosarcoma.

Expertise in
26
conditions
Dr. Matthew J. Matasar
Hematology | Oncology
Expertise in
26
conditions
Dr. Matthew J. Matasar
Hematology | Oncology
Referral may be required

Rutgers Cancer Institute Of New Jersey

195 Little Albany St, 
New Brunswick, NJ 
 (52.8 miles away)
732-475-0824
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Matthew Matasar is a Hematologist and an Oncologist practicing medicine in New Brunswick, New Jersey. Dr. Matasar is highly rated in 26 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma, B-Cell Lymphoma, and Bone Marrow Transplant. Dr. Matasar is currently accepting new patients.

Frequently Asked Questions about Dr. Mark S. Morginstin

How do I make an appointment with Dr. Mark S. Morginstin?

You can book an appointment with Dr. Mark S. Morginstin by calling their office at 215-456-3880. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Mark S. Morginstin a top-rated expert for Paget Disease of the Breast?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Mark S. Morginstin is classified as an Distinguished expert for Paget Disease of the Breast, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Mark S. Morginstin specialize in?

While Dr. Mark S. Morginstin is a Hematology, they have specific expertise in Paget Disease of the Breast, Inflammatory Breast Cancer, and Thrombocytopenia. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Mark S. Morginstin participate in research or clinical trials?

Yes. Dr. Mark S. Morginstin has published 6 articles and abstracts on conditions like Paget Disease of the Breast. You can view a list of Dr. Mark S. Morginstin's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Mark S. Morginstin accept my insurance?

Dr. Mark S. Morginstin accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 215-456-3880 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Morginstin's expertise for a condition
ConditionClose
    View All 20 Advanced Conditions
    View All 101 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile